Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial.

Yin, J. A. L., Daly, S. B., Sale, M. A., Green, S., Tobal, K., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 and Burnett, Alan Kenneth 2007. Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial. Blood 110 (11) , 167A.

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information:	Abstracts of the American Society of Hematology (ASH) Annual Meeting 2007
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	24 Oct 2022 11:56
URI:	https://orca.cardiff.ac.uk/id/eprint/49815

Actions (repository staff only)

Edit Item